Video
Author(s):
Matthew S. Davids, MD, MMSc, associate director, Dana-Farber Cancer Institute, Center for Chronic Lymphocytic Leukemia, discusses the combination of ibrutinib (Imbruvica) and obinutuzumab (Gazyva) for patients with relapsed or refractory chronic lymphocytic leukemia (CLL).
Matthew S. Davids, MD, MMSc, associate director, Center for Chronic Lymphocytic Leukemia, Dana-Farber Cancer Institute, discusses the combination of ibrutinib (Imbruvica) and obinutuzumab (Gazyva) for patients with relapsed or refractory chronic lymphocytic leukemia (CLL).
For patients with relapsed/refractory CLL, ibrutinib is the current standard therapy. There are many combination studies investigating ibrutinib plus obinutuzumab, explains Davids. In a phase Ib study, investigators are determining if the order of administration of ibrutinib and obinutuzumab affects the safety and the efficacy of the combination.